Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies

被引：0
|
作者：
Shigehisa Kitano
Toshio Shimizu
Takafumi Koyama
Takahiro Ebata
Satoru Iwasa
Shunsuke Kondo
Akihiko Shimomura
Yutaka Fujiwara
Noboru Yamamoto
Anne Paccaly
Siyu Li
Petra Rietschel
Tasha Sims
机构：
[1] National Cancer Center Hospital,Department of Experimental Therapeutics Koto
[2] Regeneron Pharmaceuticals,ku
[3] Inc.,undefined
[4] Regeneron Pharmaceuticals,undefined
[5] Inc.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2021年 / 87卷
关键词：
Cemiplimab; Anti–PD-1; Immunotherapy; Advanced tumors; Japanese patients;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：53 / 64
页数：11
相关论文
共 50 条
  • [1] Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies
    Kitano, Shigehisa
    Shimizu, Toshio
    Koyama, Takafumi
    Ebata, Takahiro
    Iwasa, Satoru
    Kondo, Shunsuke
    Shimomura, Akihiko
    Fujiwara, Yutaka
    Yamamoto, Noboru
    Paccaly, Anne
    Li, Siyu
    Rietschel, Petra
    Sims, Tasha
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (01) : 53 - 64
  • [2] Phase I study of cemiplimab, a human monoclonal antibody to programmed death (PD)-1, in Japanese patients (pts) with advanced malignancies: Results from the dose exploration.
    Kitano, Shigehisa
    Shimizu, Toshio
    Koyama, Takafumi
    Ebata, Takahiro
    Iwasa, Satoru
    Kondo, Shunsuke
    Shimomura, Akihiko
    Fujiwara, Yutaka
    Yamamoto, Noboru
    Paccaly, Anne Josee
    Baum, Clifford
    Li, Siyu
    Rietschel, Petra
    Sims, Tasha Nicholle
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [3] Interim analysis of phase 2 results for Cemiplimab, a human monoclonal antibody to programmed death-1 (PD-1), in patients with locally advanced cutaneous squamous cell carcinoma
    Migden, M. R.
    Berking, C.
    Chang, A. L. S.
    Eigentler, T. K.
    Hauschild, A.
    Hernandez-Aya, L.
    Khushalani, N., I
    Lewis, K. D.
    Meier, F.
    Modi, B.
    Rischin, D.
    Schadendorf, D.
    Schmults, C. D.
    Ulrich, C.
    Booth, J.
    Li, S.
    Mohan, K.
    Stankevich, E.
    Lowy, I
    Fury, M. G.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 161 - 162
  • [4] A phase I trial of the safety and pharmacokinetics of cemiplimab, a human monoclonal antibody to programmed death-1, in Japanese patients with advanced malignancies, including expansion cohorts for patients with non-small-cell lung cancer
    Kitano, S.
    Shimizu, T.
    Koyama, T.
    Ebata, T.
    Iwasa, S.
    Kondo, S.
    Shimomura, A.
    Fujiwara, Y.
    Yamamoto, N.
    Baum, C.
    Li, S.
    Rietschel, P.
    Sims, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 26 - 27
  • [5] A phase 1 trial of JS']JS001, a monoclonal antibody targeting programmed death-1 (PD-1) in patients with advanced or recurrent malignancies.
    Yang, Sheng
    Yang, Jianliang
    Han, Ying
    Qin, Yan
    Han, Xiaohong
    Dong, Lihou
    Feng, Hui
    Song, Haifeng
    Sun, Yan
    Shi, Yuankai
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Preliminary results from a phase 1 study of AB122, a programmed cell death-1 (PD-1) inhibitor, in patients with advanced solid malignancies
    Seitz, L. C.
    Rieger, A.
    Berry, W.
    Ashok, D.
    Direnzo, D.
    Jin, L.
    Lee, S. J.
    Park, A.
    Piovesan, D.
    Tan, J. B. L.
    Walters, M. J.
    Karakunnel, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] Cemiplimab, a human monoclonal antibody to PD-1, in patients with advanced cutaneous squamous cell carcinoma (CSCC): Clinical experience from the phase 1 and phase 2 studies
    Migden, Michael R.
    Guminski, Alexander
    Lewis, Karl D.
    Khushalani, Nikhil I.
    Papadopoulos, Kyriakos P.
    Patel, Yamini
    Andria, Michael
    Fury, Matthew G.
    Rischin, Danny
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB31 - AB31
  • [8] Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study
    Le Cesne, A.
    Marec-Berard, P.
    Blay, J. -Y.
    Gaspar, N.
    Bertucci, F.
    Penel, N.
    Bompas, E.
    Cousin, S.
    Toulmonde, M.
    Bessede, A.
    Fridman, W. H.
    Sautes-Fridman, C.
    Kind, M.
    Le Loarer, F.
    Pulido, M.
    Italiano, A.
    EUROPEAN JOURNAL OF CANCER, 2019, 119 : 151 - 157
  • [9] Phase 1 first in human study of programmed cell death receptor1(PD-1) inhibitor monoclonal antibody (mAb) JTX-4014 in adult subjects with advanced refractory solid rumor malignancies
    Papadopoulos, Kyriakos
    Falchook, Gerald
    Lakhani, Nehal
    Riley, Gosia
    Xu, Jian
    Baeck, Johan
    Gordon, Gilad
    Trehu, Elizabeth
    Wang, Judy
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [10] A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies
    Hotte, Sebastien J.
    Hirte, Hal W.
    Chen, Eric X.
    Siu, Lillian L.
    Le, Lyly H.
    Corey, Alfred
    Iacobucci, Anne
    MacLean, Martha
    Lo, Larry
    Fox, Norma Lynn
    Oza, Amit M.
    CLINICAL CANCER RESEARCH, 2008, 14 (11) : 3450 - 3455
12345